DGKα-IN-4
DGKα-IN-4 (example 432) is a DGKα inhibitor with the IC50 of 0.1 nM, extracted from patent WO2021105117. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-3 has the potential for cancer and immunology study.
Product Specifications
CAS Number
2648723-43-5
UNSPSC
12352005
Target
DGK
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dgkα-in-4.html
Solubility
10 mM in DMSO
Smiles
N#CC1=CC2=C(N(C)C(C(C#N)=C2N3CCC(C)(CC3)C4=NC5=C(O4)C=CC(C)=C5)=O)C=C1OC6COCC6
Molecular Formula
C30H29N5O4
Molecular Weight
523.58
References & Citations
[1]Schmees, Norbert, et al. Preparation of substituted aminoquinolones as DGKα inhibitors for immune activation. WO2021105117.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![Rabbit Polyclonal CCDC94 Antibody [Janelia Fluor 646]](https://cdn.genprice.uk/genprice/uk/genprice5.webp)
Rabbit Polyclonal CCDC94 Antibody [Janelia Fluor 646]
MEK1, Recombinant, Human, GST-Tag (MAP2K1, MKK1, MAPKK1, PRKMK1) discontinued
